文献速递肝肾功能剂量调整特殊人群用药

维奈克拉在终末期肾病血液透析患者中的药代动力学

Venetoclax pharmacokinetics in participants with end-stage renal disease undergoing haemodialysis.
PubMed 文献 · Br J Clin Pharmacol · 2023-11-21

本研究在6例终末期肾病(ESRD)女性透析患者和7例肾功能正常女性中单次给予维奈克拉100 mg,评估ESRD及透析对药代动力学的影响。结果显示透析不影响维奈克拉浓度,ESRD患者游离分数约高2倍,但游离峰浓度和0–48 h曲线下面积与正常组相当,半衰期为10.4–12.2 h,无需因肾功能不全进行剂量调整。

要点

  • ESRD及透析不影响维奈克拉的游离血浆浓度。
  • ESRD患者游离分数约升高2倍,但暴露量无差异。
  • 肾功能不全患者无需基于药代动力学的剂量调整。

核心结论

  • ESRD和透析不改变维奈克拉的游离血浆浓度。
  • 肾功能不全患者无需因药代动力学原因调整剂量。

研究设计与样本

  • 单次给药、开放标签的药代动力学研究。
  • 纳入6例ESRD女性透析患者(eGFR<15 mL/min)和7例肾功能正常女性(eGFR>90 mL/min)。
  • 维奈克拉单次100 mg口服,ESRD组分别在血透前和透析间期给药。

主要发现

  • ESRD组动静脉样本维奈克拉浓度无差异,提示透析不影响药代动力学。
  • ESRD组游离分数较正常肾功能组约高2倍。
  • 游离峰浓度和0–48 h曲线下面积在ESRD组与正常组间相当。
  • 各组平均半衰期为10.4–12.2 h,ESRD不影响半衰期。
  • 研究期间未观察到新的安全性信号。

关键数值与推荐

  • ESRD定义为eGFR<15 mL/min,正常肾功能定义为eGFR>90 mL/min。
  • 维奈克拉给药剂量为单次100 mg。
  • 游离峰浓度和0–48 h曲线下面积在ESRD与正常肾功能组间可比。
  • 平均半衰期范围为10.4–12.2 h。

临床怎么用

  • ESRD透析患者使用维奈克拉时无需基于药代动力学调整剂量。
  • 透析期间无需额外补充维奈克拉剂量。

局限性

  • 样本量小(ESRD组6例,正常组7例)。
  • 仅纳入女性参与者。
  • 仅评估单次100 mg剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Renal insufficiency is a common comorbidity in patients with haematological malignancies. This study aimed to assess how end-stage renal disease (ESRD) might affect the pharmacokinetics of venetoclax, a Bcl-2 inhibitor, in participants with ESRD undergoing haemodialysis. METHODS: Venetoclax was administered as a single 100-mg dose to 6 female participants with ESRD (estimated glomerular filtration rate <15 mL/min) both prior to haemodialysis and between haemodialysis days and 7 healthy female participants with normal renal function (estimated glomerular filtration rate >90 mL/min). Intensive pharmacokinetic and protein binding samples were collected from all participants. Arterial and venous samples were collected from ESRD participants during haemodialysis to assess the effect of haemodialysis on venetoclax pharmacokinetics. Pharmacokinetic parameters were estimated using noncompartmental methods. RESULTS: There was no difference in plasma venetoclax concentrations between arterial and venous samples, suggesting that haemodialysis did not affect the pharmacokinetics of venetoclax. The fraction unbound (fu ) of venetoclax was ~2-fold higher for participants with ESRD compared to participants with normal renal function. The unbound maximum plasma concentration and area under the plasma concentration-time curve from time 0 to 48 h were comparable between ESRD and normal function groups. The mean half-life ranged from 10.4 to 12.2 h across groups, demonstrating that ESRD did not affect the half-life of venetoclax. No new safety signals were observed during this study. CONCLUSION: ESRD and dialysis do not alter unbound venetoclax plasma concentrations. No pharmacokinetics driven dose adjustment is needed for patients with renal insufficiency.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Noorani B, Menon RM, Chen X, et al. Venetoclax pharmacokinetics in participants with end-stage renal disease undergoing haemodialysis. Br J Clin Pharmacol. 2023. PMID: 37855131. doi:10.1111/bcp.15935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。